The paperwork that travels with a tissue product

Records that move with the product, not records that stay behind

Most record-keeping rules describe a filing cabinet. One section of the tissue rules describes a package.

Once a donor-eligibility determination has been made, three items must accompany the product at all times. They travel with it rather than sitting in a file at the establishment.

The first is a distinct identification code affixed to the container that relates the product to the donor and to all records pertaining to it.

The second is a statement of whether, based on the results of screening and testing, the donor has been determined to be eligible or ineligible. The third is a summary of the records used to make that determination.

The code that points at a person without naming one

The identification code has a deliberate shape. It links the product to the donor and to every record about it, which is the whole point of a traceability code.

It also has a prohibition attached. Except for autologous donations, directed reproductive donations, and donations made by first-degree or second-degree blood relatives, the code must not include an individual's name, social security number, or medical record number.

A separate paragraph reinforces that. The accompanying records must not contain the donor's name or other personal information that might identify the donor.

So the traveling paperwork is designed to be fully traceable inside the system and anonymous outside it.

What the summary of records has to contain

The summary is the most substantive of the three items, and the regulation specifies four contents.

A statement that the communicable disease testing was performed by a certified laboratory. Certification here means certified to test human specimens under the Clinical Laboratory Improvement Amendments of 1988 and the associated regulations. The alternative is a laboratory that has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services.

A listing and interpretation of the results of all communicable disease tests performed. The name and address of the establishment that made the donor-eligibility determination.

And, where a product comes from a donor found ineligible on screening but released under the exception for that situation, a statement noting the reasons for the determination of ineligibility.

That last item is the one worth pausing on. The paperwork is built to carry a negative finding forward rather than drop it.

What is retained, and by whom

Alongside the traveling records there is a retention duty. Documentation must be maintained of the results and interpretation of all testing for relevant communicable disease agents, with the name and address of the testing laboratory or laboratories.

Also retained: the results and interpretation of all donor screening, and the donor-eligibility determination itself, including the name of the responsible person who made it and the date.

The quality standard is the same three-word phrase used elsewhere in the part. "All records must be accurate, indelible, and legible."

Language is addressed too. Information on the identity and relevant medical records of the donor must be in English, or retained and translated into English with a statement of authenticity from the translator identifying the translated document.

Where a record can live and still count as retained

The section answers a practical question that a lot of record rules leave open.

Records must be retained and made available for authorized inspection by or upon request from the agency. Then a definition, which the regulation states in its own words: records that can be readily retrieved from another location by electronic means are considered retained.

Retention is about retrievability, not physical custody. A record held by a partner is still the firm's retained record if it can be pulled on demand.

The clock matches the rest of the part. Records pertaining to a particular product are kept at least ten years after the date of its administration. Where that date is unknown, the clock runs ten years from its distribution, disposition or expiration, whichever is latest.

The label, and the four things that have to be on it

The labeling section in the reporting subpart adds requirements on top of the accompanying-records rule rather than replacing it.

It opens with a general duty: "You must label each HCT/P made available for distribution clearly and accurately."

Four items must appear on the label itself. The distinct identification code affixed to the container. A description of the type of product. The expiration date, if any. And any applicable warnings required by the ineligible-donor and urgent-need provisions, if physically possible.

The warnings clause has a fallback. Where it is not physically possible to include them on the label, the warnings must instead accompany the product.

Four more items that may be on the label or beside it

A second group of information is required, but the regulation lets the firm choose where it goes: either on the label or accompanying the product.

The name and address of the establishment that determines the product meets release criteria and makes it available for distribution.

The storage temperature. Other warnings, where appropriate. And instructions for use when related to the prevention of the introduction, transmission, or spread of communicable diseases.

That first item is the one a reader can actually use. The establishment that made the release decision has to be identifiable from what came with the product, which is a different party from whoever sold it.

Which products these rules reach

The labeling section sits in a subpart with a stated scope. It is implemented for nonreproductive products regulated solely under section 361 of the Public Health Service Act and the regulations in this part.

Products that are drugs or devices regulated under the act, or biological products regulated under section 351 of the Public Health Service Act, are not subject to that subpart.

The accompanying-records section sits in a different subpart with a broader reach, because the donor-eligibility procedures are pulled in by the drug and device rules as well.

Which set applies to a specific marketed product depends on its regulatory category, and that is settled by the criteria section rather than by how a product is described for sale.

What to do with this as a reader

The practical takeaway is that a legitimate tissue product does not arrive bare. A code, an eligibility statement and a records summary are supposed to be with it, and a defined set of items is supposed to be on or beside the label.

The release establishment is nameable. Storage temperature is required information. The expiration date, where one exists, belongs on the label.

What none of this establishes is whether a product does anything. These are disease-transmission and traceability controls.

And whether any particular product on sale carries this paperwork is not visible from a listing. The requirement describes what should be in the box, not what is.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 1271.55, What records must accompany an HCT/P after the donor-eligibility determination is complete; and what records must I retain? — Electronic Code of Federal Regulations, title 21, May 2005
2. 21 CFR 1271.370, Labeling — Electronic Code of Federal Regulations, title 21, June 2016
3. 21 CFR 1271.330, Applicability — Electronic Code of Federal Regulations, title 21, August 2026